British drug maker AstraZeneca announced Wednesday that it would acquire French drug developer Novexel in a deal worth $505 million.
Under the deal, AstraZeneca will pay $350 million anti-infection group Novexel's shares and another $80 million for its cash.
The British drug maker will pay further $75 million if specific targets in the development of its drug programs are reached.
Commenting on the deal, AstraZeneca said, "Building AstraZeneca's anti-infective portfolio has become a strategic priority as antibiotic-resistant bacteria pose a growing threat to human health."
Demand for new anti-infection drugs is being boosted by ever-increasing bacterial resistance to current antibiotics.
Shares in AstraZeneca were trading at 2,890.5 pence, up 1.5 pence.
- Robots to Walk Streets within 10 Years
- Bitcoin investors call for protection after collapse of two major Bitcoin platforms
- South Yorkshire cottage has been crashed into by 40 cars over last 14 years
- Doctors to Reconstruct People's Faces with Stem Cells from their Fat
- $10 Urine Test is Twice as Accurate as Existing Tests for Prostate Cancer Diagnosis